Expansion into medical devices, diagnostic reagents and regenerative medicine
First written in FY2016. 11 of 16 entries say "Restated". Latest entry: FY2020.
3 other companies' latest entry also says "Restated".
- FY2020RestatedAnnual report
「We will also actively exchange information with various universities, research institutions and operating companies, and work to launch businesses effectively and efficiently.」
The company has reaffirmed its policy of expanding into healthcare-related fields, including regenerative medicine, and launching businesses through collaboration with universities, research institutions and companies. - FY2020-Q3RestatedAnnual report
「In addition, as an engineering company that creates value through biotechnology, we will strive to provide new treatments while also approaching areas such as IT, healthcare services, diagnostics and medical devices.」
The company has reaffirmed its policy of approaching IT, healthcare services, diagnostics and medical devices, not limited to pharmaceuticals, and providing new treatments. - FY2020-Q1RestatedAnnual report
「In addition, as an engineering company that creates value through biotechnology, we will strive to provide new treatments while also approaching areas such as IT, healthcare services, diagnostics and medical devices.」
The company has reaffirmed its policy of approaching IT, healthcare services, diagnostics and medical devices, not limited to pharmaceuticals, and providing new treatments. - FY2019RestatedAnnual report
「In addition, as an engineering company that creates value through biotechnology, we will strive to provide new treatments while also approaching areas such as IT, healthcare services, diagnostics and medical devices.」
The company has reaffirmed its policy of expanding its scope to IT, healthcare services, diagnostics and medical devices, with the aim of providing new treatments. - FY2019-Q3RaisedAnnual report
「Having progressed through the GTS1.0 and GTS2.0 stages, from the current fiscal year we have established GTS3.0, with the goal of becoming an “engineering company that creates value through biotechnology.” Making maximum use of the expertise and technologies acquired through our business activities to date, we have designated pediatric diseases as a key target in addition to the rare diseases and intractable diseases we have traditionally addressed. We are working to develop and provide not only new drugs but also new forms of healthcare, with the aim of delivering comprehensive care to patients suffering from these diseases, their families and caregivers.」
The company has set out GTS3.0, expanding its business scope beyond its previous focus on medical devices and diagnostics to new forms of healthcare and comprehensive care outside new drugs, with pediatric diseases as a priority target. - FY2019-Q2RestatedAnnual report
「In addition, as an engineering company that creates value through biotechnology, we will strive to provide new treatments while also approaching areas such as IT, healthcare services, diagnostics and medical devices, with the aim of delivering comprehensive care that includes patients, their families and caregivers.」
The company has reaffirmed its policy of pursuing IT, healthcare services, diagnostics and medical devices, with the aim of providing comprehensive care and new treatments. - FY2019-Q1RaisedAnnual report
「In addition, as an engineering company that creates value through biotechnology, we will strive to provide new treatments while also approaching areas such as IT, healthcare services, diagnostics and medical devices, with the aim of delivering comprehensive care that includes patients, their families and caregivers.」
The company has expanded its business scope beyond its previous exploration of medical devices and diagnostics to include IT, healthcare services and comprehensive care. - FY2018RestatedAnnual report
「In addition, as pharmaceutical development takes time, we are broadly exploring business opportunities in healthcare-related fields, including medical devices and diagnostics, with the aim of further strengthening our stable operating environment.」
The company continues to pursue a policy of exploring business opportunities in adjacent healthcare fields, including medical devices and diagnostics. - FY2018-Q3RestatedAnnual report
「In addition, as pharmaceutical development takes time, we are broadly exploring business opportunities in healthcare-related fields, including medical devices and diagnostics, with the aim of further strengthening our stable operating environment.」
The company continues to pursue a policy of exploring business opportunities in adjacent healthcare fields, including medical devices and diagnostics. - FY2018-Q2RestatedAnnual report
「As pharmaceutical development takes time, we are also broadly exploring business opportunities in healthcare-related fields, including medical devices and diagnostics, and working toward commercialization, with the aim of further strengthening our stable operating environment.」
The company continues to pursue a policy of exploring adjacent fields outside pharmaceuticals, including medical devices and diagnostics, with the aim of commercializing them. - FY2018-Q1AdvancedAnnual report
「Furthermore, in May of the same year, we established Minerva Medica Co., Ltd., a regenerative medicine venture based in Hokkaido, through a joint investment with a Hokkaido-based company and a financial institution. We also entered into a joint research agreement with the company and Sapporo Medical University for a treatment for diabetic nephropathy using autologous bone marrow-derived mesenchymal stem cells, and are steadily expanding and advancing this business.」
The policy of exploring business opportunities in medical devices, diagnostics and regenerative medicine progressed to concrete commercialization activities, including establishing a regenerative medicine venture and entering into a joint research agreement with Sapporo Medical University. - FY2017RestatedAnnual report
「As pharmaceutical development takes time, we are also broadly exploring business opportunities in healthcare-related fields, including medical devices, diagnostics and regenerative medicine, and working toward commercialization, with the aim of further strengthening our stable operating environment.」
The company continues to pursue a policy of exploring medical devices, diagnostics, regenerative medicine and other areas outside pharmaceuticals, with the aim of commercializing them. - FY2017-Q3RestatedAnnual report
「As pharmaceutical development takes time, we are also broadly exploring business opportunities in healthcare-related fields, including medical devices, diagnostics and regenerative medicine, and working toward commercialization, with the aim of further strengthening our stable operating environment.」
The company continues to pursue a policy of exploring adjacent healthcare fields, including medical devices, diagnostics and regenerative medicine, with the aim of commercializing them. - FY2017-Q2AdvancedAnnual report
「Having become a member of the Noritsu Koki Co.,Ltd. group, we have also strengthened collaboration in regenerative medicine, an area of the group's healthcare business, and are holding ongoing discussions toward launching our new business.」
The company has progressed from exploring business opportunities in medical devices, diagnostics and regenerative medicine to strengthening collaboration with the Noritsu Koki Co.,Ltd. group's regenerative medicine business and holding discussions toward launching a new business. - FY2017-Q1RestatedAnnual report
「As pharmaceutical development takes time, we are also broadly exploring business opportunities in healthcare-related fields, including medical devices, diagnostics and regenerative medicine, and working toward commercialization, with the aim of further strengthening our stable operating environment.」
The company continues to pursue a policy of exploring adjacent fields, including medical devices, diagnostics and regenerative medicine, to offset the lengthy pharmaceutical development cycle. - FY2016First statedAnnual report
「We are also broadly exploring business opportunities in healthcare-related fields, including medical devices, diagnostics and regenerative medicine, and working toward commercialization.」
The company has set out plans to expand into adjacent healthcare fields to offset the lengthy development cycle for pharmaceuticals and establish a stable operating environment.